The new CEFALY DUAL Enhanced represents the next generation of the external Trigeminal Nerve Stimulator (eTNS) medical device and it's being introduced ahead of National Migraine and Headache Awareness Month in June. The DUAL Enhanced is a compact migraine relief and prevention device that's packed with powerful features, including all the functionality of the design that came before, plus two treatment settings. The CEFALY DUAL Enhanced device now comes with three reusable electrodes, as opposed to past devices with one.
The non-invasive device is designed to be placed on the forehead to modify the sensation of pain with either the 60-minute ACUTE setting or the 20-minute PREVENT setting for daily use, which targets the Trigeminal nerve to prevent future episodes and make life with migraines more comfortable.
Why This Trend Is Growing
- Next-gen Migraine Relief Devices
- The development of more advanced technologies for non-invasive migraine relief devices presents opportunities for further improving patient comfort and experience.
- Enhanced Etns Devices
- Continued enhancements on external trigeminal nerve stimulator devices have the potential to disrupt traditional migraine treatments, providing a safer and less invasive alternative for both patients and clinicians.
- Migraine Prevention Tools
- The rise of migraine prevention devices like the CEFALY DUAL Enhanced creates new opportunities for product innovation in the healthcare industry, specifically in the medical devices segment.
Industries Being Reshaped
- Healthcare
- The healthcare industry, particularly the medical devices sector, is primed for disruptive innovations that offer safer and more effective treatment options for patients with chronic conditions like migraines.
- Consumer Electronics
- The use of external trigeminal nerve stimulator devices for migraine relief creates an opportunity for the consumer electronics industry to develop innovative, non-invasive technologies for medical purposes.
- Pharmaceutical
- The growth of non-invasive migraine relief devices could potentially disrupt the traditional pharmaceutical industry, leading to an increased demand for drug-free treatment options for migraine sufferers.
